<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335151</url>
  </required_header>
  <id_info>
    <org_study_id>2016 -00448</org_study_id>
    <nct_id>NCT02335151</nct_id>
  </id_info>
  <brief_title>CTC Pancreatic Adenocarcinoma</brief_title>
  <official_title>Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantonsspital Winterthur KSW</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triemli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proportion of circulating tumor cells (CTC) in the postoperative phase after curative tumor
      removal of pancreatic cancer will be determined and correlated to the accordance of
      anesthesia (desflurane versus propofol)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized study will be conducted over a 36-month period to investigate
      whether commonly used anesthetics (volatile versus intravenous) have an effect on the changes
      or occurrence of CTC in patients suffering from primary pancreatic cancer undergoing curative
      surgery. The specific research question is if there are changes of the CTC count in the
      postoperative phase in the desflurane group (intervention) compared to the propofol one
      (control). A secondary question is if these changes can be correlated to tumor outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak of CTC in the postoperative phase after curative tumor removal</measure>
    <time_frame>Day 0 to Day 7</time_frame>
    <description>CTC will be counted and peak of CTC will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics of CTC after surgery up to day 7</measure>
    <time_frame>1 year</time_frame>
    <description>CTC will be counted and kinetics of CTC will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Month to Tumor recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor recurrence will be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surviving patients</measure>
    <time_frame>1 year</time_frame>
    <description>One year after surgery the number of patients still being alive will be determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Circulating Tumor Cells</condition>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General anesthesia with Desflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>General anesthesia with Propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>Apply desflurane as anesthetic</description>
    <arm_group_label>Desflurane</arm_group_label>
    <other_name>Suprane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 85

          -  ASA I-III ( American Society of Anesthesiologists)

          -  Resectable pancreatic adenocarcinoma

          -  Primary surgery

          -  No neoadjuvant therapy

          -  Written informed consent

        Exclusion Criteria:

          -  Metastatic disease

          -  Other than primary surgery (recurrence, reconstruction)

          -  Pre-operative chemotherapy

          -  Chronic opioid use

          -  Known hypersensitivity or suspected allergy to propofol, soya or egg proteins

          -  Known hypersensitivity to volatile anaesthetics (malignant hyperthermia)

          -  Pregnancy

          -  Breast feeding

          -  Enrolment in any other clinical trial during the course of this trial, 30 days prior
             to its beginning or 30 days after its completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Beck Schimmer, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatrice Beck Schimmer, Prof MD</last_name>
    <phone>+41 44 255 2032</phone>
    <email>beatrice.beck@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miodrag Filipovic, Prof. MD</last_name>
      <phone>+41714941505</phone>
      <email>miodrag.filipovic@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Breitenstein, PD. MD</last_name>
      <phone>+41522662792</phone>
      <email>stefan.breitenstein@ksw.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatrice Beck Schimmer, Prof. MD</last_name>
      <phone>+41 44 255 2032</phone>
    </contact>
    <investigator>
      <last_name>Schläpfer Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Weber, Prof. MD</last_name>
      <phone>+41444662202</phone>
      <email>markus.weber@triemli.zuerich.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating Tumor Cells</keyword>
  <keyword>Anesthesia and immunity</keyword>
  <keyword>Cell Search System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will not be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

